FDA issues prescription drug promotion guidance; FDA approves first follow-on biologic of Lilly's Humalog; drugmakers allegedly hired nurses to promote drugs
Although it's a long way from the president's desk, the Tax Cut and Jobs Act of 2017 contains plenty of good news for the life sciences industry and its marketing partners.
AbbVie adds context to CEO's comments on drug pricing; Pandora makes a play for pharma ad dollars; shortages expected of drugs manufactured in Puerto Rico
Lawmakers to investigate pricing of MS drugs; Mylan will pay $465 million to resolve EpiPen allegations; the FDA approves Pfizer's new cancer drug
Johnson & Johnson has breached the U.K.'s drug regulation code in three places in promotions for smoking cessation product Nicorette.
That's why the Coalition for Healthcare Communication is focused on creating self-regulatory guidelines.
The drugmaker has been handed a "public reprimand" by the U.K.'s Prescription Medicines Code of Practice Authority after the creative director of an unnamed agency used the company's patient support materials on its website.
Trump reiterates call to bring down drug prices; Novartis renews its focus on immunotherapies; a new bill would allow drugs to be imported
Today's ambitious marketers and media people want to be the ones to not only figure out how to work within the regulations but also to create better work than ever before.
The number of warning and untitled letters has dropped in recent years. Only four letters have been sent so far this year, compared to 28 in 2012.
The FDA declines to approve Novartis biosimilar; GSK partners with Apple's ResearchKit; drugmakers partner with Lyft for clinical trial participants
The FDA expands use for Pfizer's Prevnar 13 vaccine; an FDA panel votes in support of Novartis biosimilar; U.S. healthcare spending rises 5.5% in 2015
A government watchdog criticizes the FDA; the FDA strengthens kidney warnings for Invokana and Farxiga; people with diabetes are living longer
Social listening can help all along the value chain—from research and discovery to developing marketing plans and strategy.
Eli Lilly's lung-cancer antibody, necitumumab, has incremental benefits, according to an FDA advisory panel.
Last year's increase in CME support from manufacturers came after six straight years of declining budgets.
Three panelists from the FDA's advisory panel offered their views on the panel's decision to recommend approval of Sprout Pharmaceuticals' flibanserin
Dr. Stephen Ostroff took over as the FDA's acting commissioner when Dr. Margaret Hamburg stepped down in March.
Rep. Billy Long introduced legislation that is meant to push the FDA to implement clearer guidelines for regulating drug product information on social media.
Amgen's PSCK9 inhibitor gets a position opinion in the EU; the FDA plans to study how spouses influence perception of DTC ads; Botox may relieve depression
Drugmakers engage early with insurers; patients push for implant to be pulled from the market; about one-third of new drugs qualify for special approval pathways
Novartis reported highest drug sales in 2014; state Medicaid programs spent $1.33 billion on hepatitis-C drugs; former FDA commissioner argues against shortening regulatory review times
FDA's application programming interfaces, or openFDA, reached 6,000 users less than a year after its launch.
FDA posted a revised draft guidance document on its brief summary and adequate directions for use concerning risk information in DTC print ads to reflect "recent social science research."
FDA has named Kathleen Uhl as permanent director of the Office of Generic Drugs.
Sandoz received FDA biosimilar nod; new technique yields 25 antibiotics; Novartis sends two COPD drugs for FDA review.
GSK opts to hold onto $1.6 billion portfolio of older drugs; Sanofi upheavals continue with exit of US diabetes sales exec; Takeda gains breakthrough status on AL amyloidosis therapy.
Jakafi becomes the first drug approved for treating polycythemia vera.
Despite drugmaker discount, VA still can't afford Sovaldi without additional funds; Ousted Sanofi CEO Viehbacher faces lawsuit for an alleged kickback scheme; GSK slims sales and R&D workforce.
Amgen's Blincyto was approved for a rare form of leukemia after receiving Breakthrough Therapy designation and a Priority Review.